Published in Biochem Biophys Res Commun on March 16, 1999
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol (2002) 2.54
The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1. EMBO J (2001) 1.91
The endocannabinoid system: a general view and latest additions. Br J Pharmacol (2004) 1.77
Insulin induces long-term depression of ventral tegmental area dopamine neurons via endocannabinoids. Nat Neurosci (2013) 1.73
Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol (2001) 1.67
Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology (2009) 1.47
Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice. AAPS J (2009) 1.31
Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J Neurochem (2008) 1.18
Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. Br J Pharmacol (2001) 1.17
Polymodal activation of the endocannabinoid system in the extended amygdala. Nat Neurosci (2011) 1.15
Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology (2007) 1.15
Endocannabinoids and traumatic brain injury. Br J Pharmacol (2011) 1.14
The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol (2010) 1.11
The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet. Br J Pharmacol (2008) 1.11
An optimized GC-MS method detects nanomolar amounts of anandamide in mouse brain. Anal Biochem (2007) 1.08
Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls. Br J Pharmacol (2010) 1.07
The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol (2009) 1.05
Critical enzymes involved in endocannabinoid metabolism. Protein Pept Lett (2007) 1.04
The major central endocannabinoid directly acts at GABA(A) receptors. Proc Natl Acad Sci U S A (2011) 1.02
Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality. Life Sci (2009) 1.01
A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasion of prostate cancer cells. Biochem Biophys Res Commun (2005) 0.98
The endocannabinoid signaling system: a potential target for next-generation therapeutics for alcoholism. Mini Rev Med Chem (2007) 0.95
The endogenous cannabinoid 2-arachidonoylglycerol is intravenously self-administered by squirrel monkeys. J Neurosci (2011) 0.94
Involvement of the endogenous cannabinoid system in the effects of alcohol in the mesolimbic reward circuit: electrophysiological evidence in vivo. Psychopharmacology (Berl) (2005) 0.92
Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol. Neurosci Lett (2007) 0.91
Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity. Curr Neuropharmacol (2007) 0.90
The endocannabinoid system: directing eating behavior and macronutrient metabolism. Front Psychol (2015) 0.89
Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P. Gut (2006) 0.89
Regional distribution and effects of postmortal delay on endocannabinoid content of the human brain. Neuroscience (2008) 0.88
The cannabinergic system is implicated in the upregulation of central NGF protein by psychotropic drugs. Psychopharmacology (Berl) (2010) 0.87
Circadian rhythm of circulating levels of the endocannabinoid 2-arachidonoylglycerol. J Clin Endocrinol Metab (2015) 0.85
Central mechanisms mediating the hypophagic effects of oleoylethanolamide and N-acylphosphatidylethanolamines: different lipid signals? Front Pharmacol (2015) 0.83
Pitfalls in the sample preparation and analysis of N-acylethanolamines. J Lipid Res (2010) 0.82
Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Exp Neurol (2015) 0.80
Induction of endocannabinoid levels in juvenile rat brain following developmental chlorpyrifos exposure. Toxicol Sci (2013) 0.80
Lipidomic metabolism analysis of the endogenous cannabinoid anandamide (N-arachidonylethanolamide). J Pharm Biomed Anal (2010) 0.80
Cytosolic phospholipase A2 alpha/arachidonic acid signaling mediates depolarization-induced suppression of excitation in the cerebellum. PLoS One (2012) 0.80
Enhancement of the behavioral effects of endogenous and exogenous cannabinoid agonists by phenylmethyl sulfonyl fluoride. Neuropharmacology (2011) 0.80
Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection. Mol Neurodegener (2015) 0.79
Mechanisms of Broad-Spectrum Antiemetic Efficacy of Cannabinoids against Chemotherapy-Induced Acute and Delayed Vomiting. Pharmaceuticals (Basel) (2010) 0.79
Endocannabinoid Catabolic Enzymes Play Differential Roles in Thermal Homeostasis in Response to Environmental or Immune Challenge. J Neuroimmune Pharmacol (2015) 0.78
The initiation of synaptic 2-AG mobilization requires both an increased supply of diacylglycerol precursor and increased postsynaptic calcium. Neuropharmacology (2014) 0.78
Quantitative measurement of depolarization-induced anandamide release in human and rat neocortex. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.78
Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat. Brain Res Bull (2010) 0.78
Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia. Br J Pharmacol (2015) 0.78
Nigrostriatal denervation changes the effect of cannabinoids on subthalamic neuronal activity in rats. Psychopharmacology (Berl) (2010) 0.78
The Role of the Endocannabinoids in Suppression of the Hypothalamic-pituitary-adrenal Axis Activity by Doxepin. Iran J Basic Med Sci (2011) 0.77
Quantification of anandamide content in animal cells and tissues: the normalization makes the difference. Lipids Health Dis (2002) 0.76
Brain 2-Arachidonoylglycerol Levels Are Dramatically and Rapidly Increased Under Acute Ischemia-Injury Which Is Prevented by Microwave Irradiation. Lipids (2016) 0.76
Using the endocannabinoid system as a neuroprotective strategy in perinatal hypoxic-ischemic brain injury. Neural Regen Res (2013) 0.75
Involvement of the endocannabinoid system in the physiological response to transient common carotid artery occlusion and reperfusion. Lipids Health Dis (2017) 0.75
CB2 and GPR55 Receptors as Therapeutic Targets for Systemic Immune Dysregulation. Front Pharmacol (2016) 0.75
Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy. Parkinsons Dis (2016) 0.75
Monoglyceride lipase as a drug target: At the crossroads of arachidonic acid metabolism and endocannabinoid signaling. Pharmacol Ther (2017) 0.75
Age dependent plasticity in endocannabinoid modulation of pain processing through postnatal development. Pain (2017) 0.75
Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature (1999) 10.05
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
For whom the bird sings: context-dependent gene expression. Neuron (1998) 4.01
Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol (2001) 2.22
Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J Biol Chem (2001) 2.19
Endocannabinoids. Eur J Pharmacol (1998) 2.17
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol (2001) 2.15
The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem (2001) 2.13
Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett (2000) 2.11
Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience (2006) 2.07
Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) (2007) 1.85
An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol (1998) 1.83
Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem (1997) 1.72
Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol (2001) 1.67
Cannabinoid receptors in rat brain areas: sexual differences, fluctuations during estrous cycle and changes after gonadectomy and sex steroid replacement. Life Sci (1994) 1.58
Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma 'anandamide amidohydrolase'. FEBS Lett (1995) 1.57
Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem J (1997) 1.57
Presence of cannabinoid binding sites in the brain from early postnatal ages. Neuroreport (1993) 1.55
N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J (2000) 1.55
Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br J Pharmacol (2001) 1.54
Anandamide may mediate sleep induction. Nature (1997) 1.53
The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci U S A (1998) 1.53
The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic? Curr Med Chem (1999) 1.51
Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci (1999) 1.49
Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb Cortex (2007) 1.45
Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. Synapse (1999) 1.44
Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J (2000) 1.44
The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase. J Neurochem (2001) 1.43
Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proc Natl Acad Sci U S A (2001) 1.41
Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. J Pharmacol Exp Ther (2004) 1.38
Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem Biophys Res Commun (1999) 1.35
Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology (2000) 1.34
Anandamide uptake by human endothelial cells and its regulation by nitric oxide. J Biol Chem (2000) 1.34
Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun (1998) 1.32
Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett (2001) 1.30
The endogenous cannabinoid system and brain development. Trends Neurosci (2000) 1.28
Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol (2007) 1.28
New perspectives on enigmatic vanilloid receptors. Trends Neurosci (2000) 1.28
Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci (2006) 1.28
Novel inhibitors of brain, neuronal, and basophilic anandamide amidohydrolase. Biochem Biophys Res Commun (1997) 1.27
Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett (1999) 1.27
Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. Eur J Pharmacol (2001) 1.21
Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. Eur J Neurosci (2007) 1.20
Intense exercise increases circulating endocannabinoid and BDNF levels in humans--possible implications for reward and depression. Psychoneuroendocrinology (2011) 1.19
Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. Br J Pharmacol (2001) 1.17
The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. Eur J Biochem (2001) 1.17
A microbiological, histopathological and immunohistological study of the intragastric inoculation of Listeria monocytogenes in mice. J Comp Pathol (1992) 1.17
The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone (2008) 1.16
Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats. J Neurochem (2000) 1.16
Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake. Int J Obes (Lond) (2006) 1.16
Role and regulation of acylethanolamides in energy balance: focus on adipocytes and beta-cells. Br J Pharmacol (2007) 1.15
Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases. J Neurosci (2003) 1.15
Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. Arch Biochem Biophys (2001) 1.15
Sex steroid influence on cannabinoid CB(1) receptor mRNA and endocannabinoid levels in the anterior pituitary gland. Biochem Biophys Res Commun (2000) 1.15
Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J Neurochem (2001) 1.13
Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus. Br J Pharmacol (2007) 1.13
Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J Neurosci (2001) 1.13
Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response. Cell Mol Life Sci (2003) 1.12
Localization of mRNA expression and activation of signal transduction mechanisms for cannabinoid receptor in rat brain during fetal development. Development (1998) 1.11
Analysis of anandamide, an endogenous cannabinoid substance, and of other natural N-acylethanolamines. Prostaglandins Leukot Essent Fatty Acids (1995) 1.10
Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain. Cell Mol Life Sci (2004) 1.09
Immunohistochemical localization of anabolic and catabolic enzymes for anandamide and other putative endovanilloids in the hippocampus and cerebellar cortex of the mouse brain. Neuroscience (2007) 1.09
Activational role of cannabinoids on movement. Eur J Pharmacol (2000) 1.08
Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Brain Res Mol Brain Res (1997) 1.07
Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids with dopamine. Bioorg Med Chem Lett (2001) 1.07
Atypical location of cannabinoid receptors in white matter areas during rat brain development. Synapse (1997) 1.06
Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur J Pharmacol (2000) 1.06
Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors. Br J Pharmacol (2008) 1.04
Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chem Phys Lipids (2000) 1.04
Fatty acid synthetase activity in Mycobacterium smegmatis. Characterization of the acyl carrier protein-dependent elongating system. Biochim Biophys Acta (1977) 1.03
Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N-docosahexaenoylethanolamine in bovine retina. Arch Biochem Biophys (1999) 1.01
Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol (Oxf) (2011) 1.01
Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol. Synapse (1998) 1.01
Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration. Prostaglandins Leukot Essent Fatty Acids (2006) 1.01
Porcine epidemic abortion and respiratory syndrome (mystery swine disease). Isolation in Spain of the causative agent and experimental reproduction of the disease. Vet Microbiol (1992) 1.01
Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Eur J Pharmacol (2001) 1.01
The effect of estrogen and tamoxifen on hepatocyte proliferation in vivo and in vitro. Hepatology (1989) 1.01
The sleep inducing factor oleamide is produced by mouse neuroblastoma cells. Biochem Biophys Res Commun (1997) 1.00
Choroiditis and meningitis in experimental murine infection with Listeria monocytogenes. Eur J Clin Microbiol Infect Dis (1992) 1.00
Altered endocannabinoid signalling after a high-fat diet in Apoe(-/-) mice: relevance to adipose tissue inflammation, hepatic steatosis and insulin resistance. Diabetologia (2011) 1.00
Phosphatidic acid as the biosynthetic precursor of the endocannabinoid 2-arachidonoylglycerol in intact mouse neuroblastoma cells stimulated with ionomycin. J Neurochem (1999) 0.99
Renal Transplantation in the Presence of a Positive Cytotoxic Antibody. Transplant Proc (1988) 0.99
Sporadic, nontrauma-related, desmoid tumor of the pancreas: a rare disease-case report and literature review. Case Rep Med (2010) 0.99
Identification of Leishmania donovani amastigotes in canine tissues by immunoperoxidase staining. Res Vet Sci (1988) 0.97
Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats. Pharmacol Res (2009) 0.96
Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur J Neurosci (2001) 0.96